About Obsidian
Obsidian Therapeutics, founded in 2015, aspires to extend adoptive immunotherapy to every patient with cancer. We do this by building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients. MORE >
News
04/18/2019
Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer
Science
Overview
Obsidian Therapeutics is developing a suite of technologies that allow for exquisite control of protein activity in cells, thereby enabling tunable cell and gene therapies. These technologies will enable the creation of a powerful new class of therapies that address the safety and efficacy limitations MORE >
Advancing the Platform
Obsidian has taken the original work on destabilizing domains (DDs) performed by our scientific founder, Professor Thomas Wandless, and has substantially advanced the platform. We have created libraries of novel DDs with properties that make MORE >
Team
Paul K. Wotton, PhD
Chief Executive Officer
Paul Wotton is an accomplished leader in the biotechnology and pharmaceutical industry with experience spanning scientific research, product development and corporate growth gained over a thirty-year career. Dr. Wotton most MORE >
Steve Shamah, PhD
Senior Vice President and Head of Research
Steve Shamah joined Obsidian Therapeutics in September 2016 as Senior Vice President and Head of Research where he leads a dynamic team towards the discovery and development of next generation cell MORE >
Vipin Suri, PhD
Vice President, Discovery
Vipin Suri is the VP of Discovery at Obsidian Therapeutics and joined Obsidian’s founding team in January of 2016. Prior to Joining Obsidian, Vipin was Head of Biology at Raze Therapeutics MORE >
Celeste Richardson, PhD
Vice President, Cell Therapy
Celeste Richardson joined Obsidian Therapeutics in November of 2016 as Vice President of Cell Therapy. Prior to joining Obsidian, Celeste was at the Novartis Institutes for Biomedical Research where she led MORE >
Kirsten Kester
Senior Director of Business Development
Kirsten Kester is Senior Director of Business Development at Obsidian Therapeutics. Previously, she was Senior Director at Huron Consulting (formerly Frankel Group), where she served on the leadership team for the MORE >
Mike Briskin, PhD
Senior Advisor, Research
Mike Briskin is Senior Advisor at Obsidian Therapeutics.Dr. Briskin brings more than 20 years of industry experience in multiple areas of drug discovery, including molecular biology, immunobiology, oncology and inflammation. Prior to MORE >
Peter Barrett, PhD
Chairman
Peter Barrett is a partner at Atlas Venture and focuses on investments in therapeutics that significantly improve patients’ quality of life.
At Atlas, Peter has been involved in MORE >
Jason Gardner, D.Phil
Jason Gardner is Chief Executive Officer and Cofounder of Magenta Therapeutics. He has more than 20 years of experience in stem cell science and industry leadership roles. He worked at MORE >
Michael Gilman, PhD
Michael Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. Mike is currently Chairman and Chief Executive Officer of Arrakis Therapeutics. He is a member of the Board MORE >
Carolyn Ng, PhD
Carolyn Ng is a Managing Director of Vertex Ventures HC. At Vertex, Carolyn is responsible for driving venture investments across biotechnology, medical devices and health technology fields. In addition to MORE >
Rob Woodman
Rob Woodman is Senior Partner with Takeda Ventures Inc. and is based in London, UK. He serves as Board director or Observer at the Board of seven TVI portfolio companies, MORE >
Paul K. Wotton, PhD
Paul Wotton is an accomplished leader in the biotechnology and pharmaceutical industry with experience spanning scientific research, product development and corporate growth gained over a thirty-year career. Dr. Wotton most MORE >